PRAMIPEXOLE TABLET

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE

제공처:

SIVEM PHARMACEUTICALS ULC

ATC 코드:

N04BC05

INN (국제 이름):

PRAMIPEXOLE

복용량:

0.5MG

약제 형태:

TABLET

구성:

PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 0.5MG

관리 경로:

ORAL

패키지 단위:

100

처방전 유형:

Prescription

치료 영역:

NONERGOT-DERIVATIVE DOPAMINE RECEPTOR AGONISTS

제품 요약:

Active ingredient group (AIG) number: 0152169002; AHFS:

승인 상태:

APPROVED

승인 날짜:

2018-01-09

제품 특성 요약

_ _
_PRAMIPEXOLE Product Monograph _
_Page 1 of 59_
PRODUCT MONOGRAPH
PR
PRAMIPEXOLE
Pramipexole Dihydrochloride Tablets
0.25 mg, 0.5 mg, 1 mg & 1.5 mg
pramipexole dihydrochloride monohydrate
ANTIPARKINSONIAN AGENT / DOPAMINE AGONIST
Sivem Pharmaceuticals ULC
4705 Dobrin Street
Saint-Laurent, Quebec, Canada
H4R 2P7
www.sivem.ca
Date of Revision:
November 10, 2021
Submission control No.: 257831
_ _
_PRAMIPEXOLE Product Monograph _
_Page 2 of 59_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
...............................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND PRECAUTIONS
...................................................................................
5
ADVERSE REACTIONS
...................................................................................................
12
DRUG
INTERACTIONS....................................................................................................
21
DOSAGE AND ADMINISTRATION
...............................................................................
23
OVERDOSAGE
..................................................................................................................
26
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 27
STORAGE AND STABILITY
...........................................................................................
31
SPECIAL HANDLING INSTRUCTIONS
.........................................................................
31
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 31
PART II: SCIENTIFIC INFORMATION
..........................................................................
33
CLINICAL TRIALS
.................